FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

fabio baronti

Research Profile

Disorders

Chemicals & Drugs

Concepts & Ideas

Procedures

Physiology

Movement

Activities & Behaviors

Psychomotor Performance

Co-author Network

Publications

TOP 3
T Vanbellingen; fabio baronti; Mark Hallett; G Lopez; C Lungu; René Martin Mueri; Stephan Bohlhalter
Short and valid assessment of apraxia in Parkinson's disease.
T Vanbellingen; fabio baronti; M Bellion; B Kersten; René Martin Mueri; P Temperli; Stephan Bohlhalter
Impaired finger dexterity in Parkinson's disease is associated with praxis function.
T Vanbellingen; B Kersten; A Van de Winckel; M Bellion; fabio baronti; René Martin Mueri; Stephan Bohlhalter
A new bedside test of gestures in stroke: the apraxia screen of TULIA (AST).

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of fabio baronti (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: T Vanbellingen; fabio baronti; Mark Hallett; G Lopez; C Lungu; René Martin Mueri; Stephan Bohlhalter
Short and valid assessment of apraxia in Parkinson's disease.
Parkinsonism & related disorders 2012;18(4):348-50.
2011: T Vanbellingen; fabio baronti; M Bellion; B Kersten; René Martin Mueri; P Temperli; Stephan Bohlhalter
Impaired finger dexterity in Parkinson's disease is associated with praxis function.
Brain and cognition 2011;77(1):48-52.
2011: T Vanbellingen; B Kersten; A Van de Winckel; M Bellion; fabio baronti; René Martin Mueri; Stephan Bohlhalter
A new bedside test of gestures in stroke: the apraxia screen of TULIA (AST).
Journal of neurology, neurosurgery, and psychiatry 2011;82(4):389-92.
2008: Andreas Gebhardt; Tim Vanbellingen; fabio baronti; Bernd Kersten; Stephan Bohlhalter
Poor dopaminergic response of impaired dexterity in Parkinson's disease: Bradykinesia or limb kinetic apraxia?
Movement disorders : official journal of the Movement Disorder Society 2008;23(12):1701-6.
2007: fabio baronti
[Rehabilitation of parkinsonian patients].
Therapeutische Umschau. Revue thérapeutique 2007;64(1):29-33.
2006: Ann Van de Winckel; Hilde Feys; Suzan van der Knaap; Ruth Messerli; fabio baronti; Ruth Lehmann; Bart Van Hemelrijk; Franca Pantè; Carlo Perfetti; Willy De Weerdt
Can quality of movement be measured? Rasch analysis and inter-rater reliability of the Motor Evaluation Scale for Upper Extremity in Stroke Patients (MESUPES).
Clinical rehabilitation 2006;20(10):871-84.
2002: fabio baronti
[Psychological and cognitive problems in Parkinson disease--therapeutic possibilities].
Praxis 2002;91(10):411-7.
1995: Giovanni Fabbrini; fabio baronti; Stefano Ruggieri; Gian Luigi Lenzi
Meningioma-induced loss of antiparkinsonian response to levodopa.
Movement disorders : official journal of the Movement Disorder Society 1995;10(2):231-2.
1993: J J Anderson; D Bravi; R Ferrari; T L Davis; fabio baronti; Thomas N Chase; F Dagani
No evidence for altered muscle mitochondrial function in Parkinson's disease.
Journal of neurology, neurosurgery, and psychiatry 1993;56(5):477-80.
1993: Fabrizio Stocchi; L Bramante; A Monge; F Viselli; fabio baronti; E Stefano; Stefano Ruggieri
Apomorphine and lisuride infusion. A comparative chronic study.
Advances in neurology 1993;60():653-5.
1992: fabio baronti; M Maral Mouradian; T L Davis; M Giuffra; G Brughitta; Katherine Conant; Thomas N Chase
Continuous lisuride effects on central dopaminergic mechanisms in Parkinson's disease.
Annals of neurology 1992;32(6):776-81.
1992: fabio baronti; M Maral Mouradian; Katherine Conant; M Giuffra; G Brughitta; Thomas N Chase
Partial dopamine agonist therapy of levodopa-induced dyskinesias.
Neurology 1992;42(6):1241-3.
1992: fabio baronti; T L Davis; R C Boldry; M Maral Mouradian; Thomas N Chase
Deprenyl effects on levodopa pharmacodynamics, mood, and free radical scavenging.
Neurology 1992;42(3 Pt 1):541-4.
1992: I J Heuser; fabio baronti; C A Marin; N Ma; G R Merriam; Thomas N Chase; M Maral Mouradian
Growth hormone secretion in Alzheimer's disease: 24-hour profile of basal levels and response to stimulation and suppression studies.
Neurobiology of aging 1992;13(2):255-60.
1991: fabio baronti; Stefano Ruggieri; M Maral Mouradian; A Bonamartini; P Bocciarelli; Maria Francesca De Pandis; Thomas N Chase; A Agnoli
[Changes in the nigrostriatal dopamine receptor compartment after continuous dopaminergic infusions in Parkinson disease].
Rivista di neurologia 1991;61(6):210-4.
1991: M Maral Mouradian; J Blin; M Giuffra; I J Heuser; fabio baronti; J Ownby; Thomas N Chase
Somatostatin replacement therapy for Alzheimer dementia.
Annals of neurology 1991;30(4):610-3.
1991: Stefano Ruggieri; Fabrizio Stocchi; fabio baronti; F Viselli; R Horowski; C Lucarelli; A Agnoli
Antagonist effect of terguride in Parkinson's disease.
Clinical neuropharmacology 1991;14(5):450-6.
1991: fabio baronti; Katherine Conant; M Giuffra; T L Davis; G Brughitta; Michael Iadarola; W H Berrettini; Thomas N Chase; M Maral Mouradian
Opioid peptides in Parkinson's disease: effects of dopamine repletion.
Brain research 1991;560(1-2):92-6.
1991: T L Davis; G Brughitta; fabio baronti; M Maral Mouradian
Acute effects of pulsatile levodopa administration on central dopamine pharmacodynamics.
Neurology 1991;41(5):630-3.
1991: M Maral Mouradian; I J Heuser; fabio baronti; M Giuffra; Katherine Conant; T L Davis; Thomas N Chase
Comparison of the clinical pharmacology of (-)NPA and levodopa in Parkinson's disease.
Journal of neurology, neurosurgery, and psychiatry 1991;54(5):401-5.
1990: M Maral Mouradian; I J Heuser; fabio baronti; Thomas N Chase
Modification of central dopaminergic mechanisms by continuous levodopa therapy for advanced Parkinson's disease.
Annals of neurology 1990;27(1):18-23.
1989: Thomas N Chase; fabio baronti; Giovanni Fabbrini; I J Heuser; Jorge L Juncos; M Maral Mouradian
Rationale for continuous dopaminomimetic therapy of Parkinson's disease.
Neurology 1989;39(11 Suppl 2):7-10; discussion 19.
1989: M Maral Mouradian; I J Heuser; fabio baronti; Giovanni Fabbrini; Jorge L Juncos; Thomas N Chase
Pathogenesis of dyskinesias in Parkinson's disease.
Annals of neurology 1989;25(5):523-6.
1988: Fabrizio Stocchi; Stefano Ruggieri; Angelo Antonini; fabio baronti; G Brughitta; P Bellantuono; D Bravi; A Agnoli
Subcutaneous lisuride infusion in Parkinson's disease: clinical results using different modes of administration.
Journal of neural transmission. Supplementum 1988;27():27-33.
1987: Fabrizio Stocchi; Stefano Ruggieri; fabio baronti; P Bellantuono; G Brughita; Angelo Antonini; D Bravi; A Agnoli
[On-off phenomena in Parkinson's disease. Continuous dopaminergic stimulation].
La Clinica terapeutica 1987;122(2):83-8.
1986: Stefano Ruggieri; Fabrizio Stocchi; alessandro denaro; fabio baronti; A Agnoli
The role of MAO-b inhibitors in the treatment of Parkinson's disease.
Journal of neural transmission. Supplementum 1986;22():227-33.